EMV Capital Limited
EMV Capital Ltd (EMVC) is a London-based pan-European award-winning investor focused on B2B companies in the industrial high-tech, clean energy, resource efficiency, circular economy, smart cities, healthcare, and transportation sectors.
EMVC invests in and provides advisory services related to, investments that involve a range of technologies including robotics and AI, machine vision, materials science, IoT, advanced engineering and power electronics. EMVC’s model is to develop a customised investment strategy for each company, combining its network of investors from Family Offices, Wealth Managers, Institutional VC investors and Corporate VC funds.
While not an impact investor, EMVC understand the importance and value of environmental sustainability and ethical investment principles, reflecting this within its investment thesis and EMVC recognises the benefits of corporate engagement for early-stage technology companies, with EMVC’s team having led and structured investments alongside some of the world’s leading corporations, including ABB, Philips Lighting, Evonik Industries, Mitsubishi and Flex.
Founded by Dr. Ilian Iliev, EMVC has a unique multidisciplinary team with expertise in investment, deep industry, corporate finance and M&A. EMV Capital Limited is an appointed representative of Sapphire Capital Limited, which is authorised and regulated by the Financial Conduct Authority. EMV Capital is also exclusive advisor to the EMVC Evergreen EIS Fund.
B2B industiral technology - clean energy, resource efficiency, health care, medtech, smart cities, transportation, robotics, AI
Key team members
Dr. Ilian Iliev is Managing Director of EMV Capital where he also leads the investment advisory team. Ilian spun-out EMV Capital out of EcoMachines Ventures, which was founded in 2013. Prior to that he co-founded and was CEO of CambridgeIP Ltd (2006-2012), which he built into a leading market and technology business intelligence provider in the UK (partial exit through sale of data & software business to multi-billion US investment fund). In the late 1990s, he co-founded and led 100-person family business in Southern Africa in the electrical industry, with a focus on turnkey industrial installations. He is a Board member at a number of EMVC portfolio companies, including Pointgrab (Israel), Sofant Technologies (UK), Q-Bot (UK), Vortex Biosciences Inc (USA), Wanda Health Inc (USA)
Ilian holds a PhD from Cambridge University’s Judge Business School, focused on Venture Capital business models in emerging economies; MCom in Economics, and BA in Politics, Economics and International Relations from the University of Witwatersrand, where he was voted Best Political Science Student in South Africa in 1997. He has published widely on issues in the energy, healthcare, innovation finance and entrepreneurship. He is an Associate Fellow at Chatham House, focused on energy and resource efficiency.
Ian is former Director at the Carbon Trust, where he was responsible for managing the investment portfolio and leading the commercial development of the Carbon Trust innovation activities. He qualified as an Engineer in South Africa and was awarded a Master of Business Administration from Cranfield School of Management, UK. Earlier in his career he worked in venture capital, corporate venture and international business development in the engineering and environmental sectors. He has founded and invested in a number of successful new ventures in the engineering and technology fields.
Harry evaluates investment opportunities, carries out due diligence analysis, and develops internal processes for fund operation. Prior to EMV Capital, Harry worked as an Associate within an IP consultancy firm, analysing patent data and advising on patent strategy. Harry holds a BA and MSci in Natural Sciences from The University of Cambridge.
Recycling Technologies patented technology is classified as feedstock recycling and uses thermal cracking to process residual plastic waste into a liquid hydrocarbon feedstock for use in the manufacturing of new polymers.
Insight has developed an Akinetic, all semiconductor laser: a platform technology with a step-change in performance for multiple applications including Industrial maintenance and processes monitoring for resource efficiency, LiDAR, and Medical Imaging.
Example portfolio companies
Q-Bot develops robots for the building and engineering industry, assisting human labour where there are significant cost or health and safety benefits. Their first application is in underfloor insulation for Victorian and early-20th century housing, leading to significant decreases in heat loss and improvements in comfort levels for residents.
Winner of IEEE Invention and Entrepreneurship in Robotics and Automation Award at the 2015 IEEE/IFR Joint Forum on IERA
Winner of Innovation Achievers Award (Highly Commended) at the 2015 CIOB International Innovation & Research Awards
Nominated in the Energy Saving Product of the Year category at the 2015 CIBSE Building Performance Awards.
Developing a unique solution to steer the radio signal towards the receiver—improving range and performance of the antenna, whilst reducing the power required to operate the network, thereby avoiding the need for expensive cooling systems. Sofant’s patented smart antenna technology enables the steering of radio signals in future wireless systems in the 5G and SatCom space.
A US-based oncology diagnostic company, developing a novel liquid biopsy automated instrument (VTX-1) and microfluidic cartridge for the isolation of circulating tumour cells from whole blood without the need for any pre-treatment. Vortex Biosciences’ main mission is to become the innovation leader in CTC capture technology delivering diagnostic tests that improve therapeutic decisions and save lives. The key potential is to revolutionise cancer diagnosis leading to better therapeutic outcomes. Its technology integrates cancer biology, microfluidic engineering, clinical research and the identification of cancer therapies and drug targets.
A remote monitoring healthcare analytics and management company for primary care patients with chronic diseases based in San Francisco. Wanda’s ambition is to significantly control and reduce hospitalisation rates through a Remote Monitoring System (RMS) that collects data from patients’ home to clinicians highlighting the high risks and allowing the action to prevent them. This life personalised medicine combined with secure computing and revolutionary data-mining and analytics improves the quality of life for people with chronic conditions, initially focused on congestive heart failure (CHF). Chronic disease in the US is accounted for 80% of the total health care bill representing a US$1.4 trillion expenditure. This could be significantly decreased through a severe chronic disease management and appropriate clinical measures.